What is Retatrutide?
An introduction to retatrutide, the investigational triple agonist showing promising weight loss results. Learn how it differs from tirzepatide and semaglutide.
What is Retatrutide?
Retatrutide is an investigational medication that activates three hormone receptors: GIP, GLP-1, and glucagon. It’s being developed by Eli Lilly for obesity and diabetes.
Key Facts
| Fact | Detail |
|---|---|
| Status | Phase 3 clinical trials |
| Not Yet Approved | Investigational drug |
| Developer | Eli Lilly |
| Weight Loss (Phase 2) | Up to 24% |
How Is It Different?
| Medication | Receptors |
|---|---|
| Semaglutide | GLP-1 only |
| Tirzepatide | GIP + GLP-1 |
| Retatrutide | GIP + GLP-1 + Glucagon |
Why Add Glucagon?
The glucagon receptor may:
- Increase calorie burning
- Enhance fat breakdown
- Boost metabolic rate
When Might It Be Available?
Retatrutide is in Phase 3 trials (TRIUMPH program). If successful, potential approval could come in 2026-2027, but this is not guaranteed.
Current Status
You cannot get retatrutide outside of clinical trials. It is not approved or available for prescription.
This guide is for educational purposes only. Retatrutide is an investigational drug.
Sources & Citations
- 1
Disclaimer: This article is for educational purposes only and does not constitute medical advice. The information presented is based on current research but should not be used for diagnosis, treatment, or prevention of any disease. Always consult a qualified healthcare provider before making health decisions.